gamma-aminobutyric acid has been researched along with Behavior Disorders in 135 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients diagnosed with fibromyalgia according to the American College of Rheumatology criteria, randomized to placebo or 300, 450, or 600 mg/day pregabalin, and with ≥ 1 postbaseline pain score were included." | 8.86 | Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010) |
| "Comorbid conditions are common among patients with fibromyalgia and their presence is not associated with altered pregabalin efficacy." | 8.86 | Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010) |
| "A 28-year-old female patient developed an increased temperature and neuropsychiatric symptoms after receiving 75 mg pregabalin therapy for neuralgia." | 7.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Clinicians should be alert to the serious neuropsychiatric symptoms and thrombocytopenia associated with the use of pregabalin." | 7.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| ") and restless legs syndrome treated with ropinirole and gabapentin, will be discussed." | 4.89 | Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013) |
| "Patients diagnosed with fibromyalgia according to the American College of Rheumatology criteria, randomized to placebo or 300, 450, or 600 mg/day pregabalin, and with ≥ 1 postbaseline pain score were included." | 4.86 | Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010) |
| "Comorbid conditions are common among patients with fibromyalgia and their presence is not associated with altered pregabalin efficacy." | 4.86 | Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. ( Bhadra, P; Petersel, D, 2010) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "A 28-year-old female patient developed an increased temperature and neuropsychiatric symptoms after receiving 75 mg pregabalin therapy for neuralgia." | 3.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "Clinicians should be alert to the serious neuropsychiatric symptoms and thrombocytopenia associated with the use of pregabalin." | 3.80 | Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report. ( Liu, W; Qin, F; Qu, C; Xie, Y, 2014) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "Gabapentin appeared to be a safe and efficacious medication to reduce cocaine usage in a community sample of psychiatric patients." | 2.71 | Gabapentin reduces cocaine use among addicts from a community clinic sample. ( Coomaraswamy, S; Raby, WN, 2004) |
| "Gabapentin was hypothesized to reduce cocaine use by restoring inhibitory GABAergic feedback on ascending dopaminergic projections to nucleus accumbens neurons." | 2.71 | Gabapentin reduces cocaine use among addicts from a community clinic sample. ( Coomaraswamy, S; Raby, WN, 2004) |
| "Vigabatrin (VGB) is an effective add-on anti-epileptic drug." | 2.68 | Retrospective study of vigabatrin and psychiatric behavioural disturbances. ( Wong, IC, 1995) |
| "Subsequently, two trials on nonorganic sleep disorders in generalized anxiety disorder (GAD) and bruxism, as well as two trials on organic sleep disorders, i." | 2.49 | Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013) |
| "Pediatric epilepsy is a common, chronic, and challenging physical illness for children and their families." | 2.46 | Psychiatric concerns in pediatric epilepsy. ( Bujoreanu, IS; DeMaso, DR; Ibeziako, P, 2010) |
| "Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia." | 2.44 | Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. ( Kim, Y; Tampi, RR; Wilkins, KM, 2008) |
| "The key words 'dementia', 'Alzheimer's disease' and 'gabapentin' were used." | 2.44 | Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence. ( Kim, Y; Tampi, RR; Wilkins, KM, 2008) |
| " In the meantime, a review of the established pharmacokinetic and pharmacodynamic activities of these agents is the first step in defining their optimal uses and limitations in the psychiatric setting." | 2.40 | Pharmacokinetics of new anticonvulsants in psychiatry. ( Morris, HH, 1998) |
| " The classic AEDs had numerous problems, ranging from inconvenient dosing schedules to frequent side effects due to active metabolites and common drug interactions; newer agents have been developed to avoid some of these pitfalls." | 2.40 | Pharmacokinetics of new anticonvulsants in psychiatry. ( Morris, HH, 1998) |
| " Finally, gabapentin is a very safe add-on medication." | 2.39 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 2.39 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "Among psychiatric disorders the acute symptoms of schizophrenia are exacerbated by enhanced GABA-ergic function." | 2.36 | Pharmacology of GABA. ( Meldrum, B, 1982) |
| "All patients had substance use disorders, the large majority (72 %) to more than one substance." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| "Fifty-eight percent had an opioid use disorder, again mostly in combination with other drugs and/or alcohol." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| "A patient with Usher syndrome and psychiatric symptoms is described and the difficulties in psychiatric assessment in her case are discussed." | 1.35 | Usher syndrome and psychiatric symptoms: a challenge in psychiatric management. ( Grubic, VN; Rijavec, N, 2009) |
| " Pantogam was administered in dosage 750-3000 mg per day along with traditional and atypical neuroleptics." | 1.34 | [Pantogam in daily psychiatric practice]. ( Bogdan, MN; Kontsevoĭ, VA; Riakhovskiĭ, VV; Rotshteĭn, VG, 2007) |
| "Several brain disorders, e." | 1.29 | Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists? ( Polc, P, 1995) |
| "Vigabatrin is an anticonvulsant drug with a relatively favourable side-effect profile." | 1.29 | Vigabatrin and behaviour disorders: a retrospective survey. ( Ring, H; Schmitz, B; Thomas, L; Trimble, M, 1996) |
| "Patients with unipolar depression who received a dexamethasone suppression test had no correlation between nonsuppression of cortisol secretion and plasma levels of GABA." | 1.27 | Plasma GABA levels in psychiatric illness. ( Petty, F; Sherman, AD, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (31.11) | 18.7374 |
| 1990's | 18 (13.33) | 18.2507 |
| 2000's | 30 (22.22) | 29.6817 |
| 2010's | 38 (28.15) | 24.3611 |
| 2020's | 7 (5.19) | 2.80 |
| Authors | Studies |
|---|---|
| Tran, MN | 1 |
| Maynard, KR | 1 |
| Spangler, A | 1 |
| Huuki, LA | 1 |
| Montgomery, KD | 1 |
| Sadashivaiah, V | 1 |
| Tippani, M | 1 |
| Barry, BK | 1 |
| Hancock, DB | 1 |
| Hicks, SC | 1 |
| Kleinman, JE | 2 |
| Hyde, TM | 1 |
| Collado-Torres, L | 1 |
| Jaffe, AE | 1 |
| Martinowich, K | 1 |
| Larsen, KM | 1 |
| Liu, S | 1 |
| Men, X | 1 |
| Guo, Y | 1 |
| Cai, W | 1 |
| Wu, R | 1 |
| Gao, R | 1 |
| Zhong, W | 1 |
| Guo, H | 1 |
| Ruan, H | 1 |
| Chou, S | 1 |
| Mai, J | 1 |
| Ping, S | 1 |
| Jiang, C | 1 |
| Zhou, H | 1 |
| Mou, X | 1 |
| Zhao, W | 1 |
| Lu, Z | 1 |
| Kang, E | 1 |
| Song, J | 1 |
| Lin, Y | 1 |
| Park, J | 1 |
| Lee, JH | 1 |
| Hussani, Q | 1 |
| Gu, Y | 1 |
| Ge, S | 1 |
| Li, W | 1 |
| Hsu, KS | 1 |
| Berninger, B | 1 |
| Christian, KM | 1 |
| Song, H | 1 |
| Ming, GL | 1 |
| Feld, GB | 1 |
| Born, J | 1 |
| Hirjak, D | 1 |
| Wolf, RC | 1 |
| Northoff, G | 1 |
| Li, S | 2 |
| Zhang, G | 1 |
| Yang, J | 1 |
| Kim, HK | 1 |
| Blumberger, DM | 1 |
| Downar, J | 1 |
| Daskalakis, ZJ | 2 |
| Chhabra, H | 1 |
| Thimmashetty, VH | 1 |
| Shivakumar, V | 1 |
| Venkatasubramanian, G | 1 |
| Narayanswamy, JC | 1 |
| Bast, T | 1 |
| Pezze, M | 1 |
| McGarrity, S | 1 |
| Burns, SB | 1 |
| Szyszkowicz, JK | 1 |
| Luheshi, GN | 1 |
| Lutz, PE | 1 |
| Turecki, G | 1 |
| Ordyan, NE | 1 |
| Akulova, VK | 1 |
| Mironova, VI | 1 |
| Otellin, VA | 1 |
| Andersson, JD | 1 |
| Matuskey, D | 1 |
| Finnema, SJ | 1 |
| Konen, C | 1 |
| Niederst, E | 1 |
| Molteni, R | 1 |
| Macchi, F | 1 |
| Riva, MA | 1 |
| Amos, LB | 1 |
| Grekowicz, ML | 1 |
| Kuhn, EM | 1 |
| Olstad, JD | 1 |
| Collins, MM | 1 |
| Norins, NA | 1 |
| D'Andrea, LA | 1 |
| Saletu, B | 1 |
| Anderer, P | 1 |
| Saletu-Zyhlarz, GM | 1 |
| Silveri, MM | 1 |
| Waschkies, CF | 1 |
| Bruns, A | 1 |
| Müller, S | 1 |
| Kapps, M | 1 |
| Borroni, E | 1 |
| von Kienlin, M | 1 |
| Rudin, M | 1 |
| Künnecke, B | 1 |
| Qu, C | 1 |
| Xie, Y | 1 |
| Qin, F | 1 |
| Liu, W | 1 |
| Joshee, S | 1 |
| Vasudevan, A | 1 |
| Kalia, M | 1 |
| Costa E Silva, J | 1 |
| Kim, S | 2 |
| Hwang, Y | 1 |
| Webster, MJ | 2 |
| Lee, D | 1 |
| Heaney, CF | 1 |
| Kinney, JW | 1 |
| Bastiaens, L | 1 |
| Galus, J | 1 |
| Mazur, C | 1 |
| Schür, RR | 1 |
| Draisma, LW | 1 |
| Wijnen, JP | 1 |
| Boks, MP | 1 |
| Koevoets, MG | 1 |
| Joëls, M | 1 |
| Klomp, DW | 1 |
| Kahn, RS | 1 |
| Vinkers, CH | 1 |
| Bjørn-Yoshimoto, WE | 1 |
| Underhill, SM | 1 |
| Rice, LJ | 1 |
| Lagopoulos, J | 1 |
| Brammer, M | 1 |
| Einfeld, SL | 1 |
| Chen, M | 1 |
| Liao, C | 1 |
| Chen, S | 1 |
| Ding, Q | 1 |
| Zhu, D | 1 |
| Liu, H | 1 |
| Yan, X | 1 |
| Zhong, J | 1 |
| Shepard, R | 1 |
| Heslin, K | 1 |
| Coutellier, L | 1 |
| Uhlhaas, PJ | 1 |
| Gajwani, R | 1 |
| Gross, J | 1 |
| Gumley, AI | 1 |
| Lawrie, SM | 1 |
| Schwannauer, M | 1 |
| Levy, BS | 1 |
| Pinna, G | 1 |
| Costa, E | 3 |
| Guidotti, A | 3 |
| Rijavec, N | 1 |
| Grubic, VN | 1 |
| Chen, Y | 1 |
| Fu, AK | 1 |
| Ip, NY | 1 |
| Mansfield, AS | 1 |
| Qian, Q | 1 |
| Bujoreanu, IS | 1 |
| Ibeziako, P | 1 |
| DeMaso, DR | 1 |
| Agam, G | 1 |
| Ben-Shachar, D | 1 |
| Gibbons, RD | 1 |
| Hur, K | 1 |
| Brown, CH | 1 |
| Mann, JJ | 1 |
| Bhadra, P | 1 |
| Petersel, D | 1 |
| Song, X | 1 |
| Wang, H | 1 |
| Zheng, L | 1 |
| Chen, D | 1 |
| Wang, Z | 1 |
| Feuerstein, TJ | 1 |
| Kammerer, M | 1 |
| Lücking, CH | 1 |
| Moser, A | 1 |
| Cortes-Romero, C | 1 |
| Galindo, F | 1 |
| Galicia-Isasmendi, S | 1 |
| Flores, A | 1 |
| Grayson, DR | 2 |
| Méndez, P | 1 |
| Bacci, A | 1 |
| Olmos-Serrano, JL | 1 |
| Corbin, JG | 1 |
| Masiulis, I | 1 |
| Yun, S | 1 |
| Eisch, AJ | 1 |
| Radhu, N | 1 |
| Guglietti, CL | 1 |
| Farzan, F | 1 |
| Barr, MS | 1 |
| Arpin-Cribbie, CA | 1 |
| Fitzgerald, PB | 1 |
| Ritvo, P | 1 |
| Medvedev, VE | 1 |
| Epifanov, AV | 1 |
| Zverev, KV | 1 |
| Chang, L | 1 |
| Cloak, CC | 1 |
| Ernst, T | 1 |
| BORROMEI, A | 1 |
| NUCCI, U | 1 |
| FEITELEVICH, J | 2 |
| ZIPILIVAN, M | 1 |
| MORRONI, OB | 1 |
| SZUKALSKI, B | 1 |
| WYSOKOWSKI, J | 1 |
| MURAKAMI, B | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Cazzato, G | 1 |
| Bava, A | 1 |
| Raby, WN | 1 |
| Coomaraswamy, S | 1 |
| Fujimori, S | 1 |
| Yoneda, Y | 1 |
| Dykens, EM | 1 |
| Sutcliffe, JS | 1 |
| Levitt, P | 1 |
| Buonopane, A | 1 |
| Petrakis, IL | 1 |
| Gálvez, R | 1 |
| Marsal, C | 1 |
| Vidal, J | 1 |
| Ruiz, M | 1 |
| Rejas, J | 1 |
| Amin, Z | 1 |
| Mason, GF | 1 |
| Cavus, I | 1 |
| Krystal, JH | 1 |
| Rothman, DL | 1 |
| Epperson, CN | 1 |
| Lanctôt, KL | 1 |
| Herrmann, N | 1 |
| Rothenburg, L | 1 |
| Eryavec, G | 1 |
| Sommer, BR | 1 |
| Fenn, HH | 1 |
| Ketter, TA | 1 |
| Bozikas, VP | 1 |
| Garyfallos, G | 1 |
| Nikolaidis, N | 1 |
| Partsafyllidis, D | 1 |
| Fokas, K | 1 |
| Kim, Y | 1 |
| Wilkins, KM | 1 |
| Tampi, RR | 1 |
| Bras, M | 1 |
| Chen, YT | 1 |
| Collins, LL | 1 |
| Chang, SS | 1 |
| Chang, C | 1 |
| Kontsevoĭ, VA | 1 |
| Rotshteĭn, VG | 1 |
| Bogdan, MN | 1 |
| Riakhovskiĭ, VV | 1 |
| Smith, DF | 1 |
| Neethling, AC | 1 |
| McCarthy, B | 1 |
| Taljaard, JJ | 1 |
| Morley, JE | 1 |
| Krogsgaard-Larsen, P | 1 |
| Hall, ED | 1 |
| Braestrup, C | 1 |
| Nielsen, M | 1 |
| Wunderlich, H | 1 |
| Wunderlich, HP | 1 |
| Chapman, A | 1 |
| Keane, PE | 1 |
| Meldrum, BS | 1 |
| Simiand, J | 1 |
| Vernieres, JC | 1 |
| Honorato Pérez, JM | 1 |
| Azanza Perea, JR | 1 |
| Cuena Boy, R | 1 |
| Walker, JE | 1 |
| Oliverio, A | 1 |
| Castellano, C | 1 |
| Puglisi-Allegra, S | 1 |
| Coyle, JT | 1 |
| Singer, H | 1 |
| Beaulieu, M | 1 |
| Johnston, MV | 1 |
| Rossor, M | 1 |
| Meldrum, B | 1 |
| Barbosa, ER | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| de Assis, JL | 1 |
| Petty, F | 1 |
| Sherman, AD | 1 |
| Bracha, HS | 1 |
| Enna, SJ | 2 |
| Hare, TA | 1 |
| Kuroda, H | 1 |
| Ogawa, N | 1 |
| Yamawaki, Y | 1 |
| Nukina, I | 1 |
| Ofuji, T | 1 |
| Yamamoto, M | 1 |
| Otsuki, S | 1 |
| Zimmer, R | 1 |
| Teelken, AW | 1 |
| Meier, KD | 1 |
| Ackenheil, M | 1 |
| Zander, KJ | 1 |
| Polc, P | 1 |
| Sherif, FM | 1 |
| Ahmed, SS | 1 |
| Ryback, R | 1 |
| Ryback, L | 1 |
| Schmidt, D | 1 |
| Krämer, G | 1 |
| Gorkin, VZ | 1 |
| Kamyshanskaia, NS | 1 |
| Kirkel', AZ | 1 |
| Medvedev, ME | 1 |
| Moskvitina, TA | 1 |
| Shepherd, M | 1 |
| Fricchione, GL | 1 |
| Mendoza, A | 1 |
| Stefano, GB | 1 |
| Wong, IC | 1 |
| Thomas, L | 1 |
| Trimble, M | 1 |
| Schmitz, B | 1 |
| Ring, H | 1 |
| Rye, DB | 1 |
| Sirtori, C | 1 |
| Chouinard, G | 1 |
| Beauclair, L | 1 |
| Bélanger, MC | 1 |
| Scearce-Levie, K | 1 |
| Chen, JP | 1 |
| Gardner, E | 1 |
| Hen, R | 1 |
| Krishnamoorthy, ES | 1 |
| Trimble, MR | 1 |
| Dallocchio, C | 1 |
| Buffa, C | 1 |
| Mazzarello, P | 1 |
| Benes, FM | 1 |
| Taylor, JB | 1 |
| Cunningham, MC | 1 |
| Lindenmayer, JP | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 2 |
| Bozikas, V | 1 |
| Bascialla, F | 1 |
| Yulis, P | 1 |
| Savvidou, I | 1 |
| Karavatos, A | 1 |
| Davis, J | 1 |
| Pappas, GD | 1 |
| Pesold, C | 1 |
| Lopez-Mato, AM | 1 |
| Boullosa, O | 1 |
| Márquez, C | 1 |
| Illa, G | 1 |
| Vieitez, A | 1 |
| Megna, JL | 1 |
| Devitt, PJ | 1 |
| Sauro, MD | 1 |
| Lapin, I | 1 |
| Morris, HH | 1 |
| Sussman, N | 1 |
| Durkin, JP | 1 |
| Lamberts, SW | 1 |
| Klijn, JG | 1 |
| Birkenhäger, JC | 1 |
| Lloyd, KG | 2 |
| Sytinsky, IA | 1 |
| Soldatenkov, AT | 1 |
| Lajtha, A | 1 |
| Paulson, GW | 1 |
| Vinar, O | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Linnoila, M | 1 |
| Viukari, M | 1 |
| Kietala, O | 1 |
| Reynolds, EH | 1 |
| Perry, TL | 1 |
| Dunn, HG | 1 |
| Ho, HH | 1 |
| Crichton, JU | 1 |
| Oelschläger, H | 1 |
| Khaunina, RA | 1 |
| Lapin, IP | 1 |
| Perrault, G | 1 |
| Zivkovic, B | 1 |
| Gaio, JM | 1 |
| Pollak, P | 1 |
| Hommel, M | 1 |
| Perret, J | 1 |
| Roberts, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia[NCT00230776] | Phase 3 | 740 participants | Interventional | 2005-10-31 | Completed | ||
| A 13-week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia[NCT00645398] | Phase 3 | 751 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.[NCT00333866] | Phase 3 | 747 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| An Innovative Smartphone-enabled Health Coaching Intervention for Youth Diagnosed With Major Depressive Disorders[NCT03406052] | 168 participants (Anticipated) | Interventional | 2018-01-19 | Suspended (stopped due to New funding required) | |||
| Remote Effects of Stroke on Cerebral Metabolism. Evaluation With Positron Emission Tomography and Proton Magnetic Resonance Spectroscopy[NCT00063180] | 70 participants | Observational | 2003-06-19 | Completed | |||
| Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair[NCT02292095] | Phase 4 | 260 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.94 |
| Pregabalin 300 mg | -8.11 |
| Pregabalin 450 mg | -12.79 |
| Pregabalin 600 mg | -8.38 |
Daily pain diary consists of 11-point NRS ranging from 0(no pain) to 10(worst possible pain). Participants rated their pain during past 24 hours, self-assessment done daily at awakening. Baseline=Last 7 available pain scores before taking study medication up to and including Day 1. Final weekly (endpoint) mean pain score is defined as the mean pain score from the last 7 pain diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.73 |
| Pregabalin 300 mg | -1.06 |
| Pregabalin 450 mg | -1.29 |
| Pregabalin 600 mg | -0.96 |
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The endpoint (up to week 14) mean quality of sleep score was based on Least Squares (LS) Means using ANCOVA, with treatment group and center in the model and the baseline mean sleep score used as the covariate. Final weekly (endpoint) mean sleep quality score is defined as the mean sleep quality score from the last 7 sleep diary entries in the study while the participant was on study medication. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -0.94 |
| Pregabalin 300 mg | -1.42 |
| Pregabalin 450 mg | -1.72 |
| Pregabalin 600 mg | -1.95 |
MAF is a 16-item self-administered questionnaire that yields a Global Fatigue Index (GFI), measures 4 dimensions of fatigue: degree and severity, amount of distress it causes, its timing and degree to which fatigue interferes with activities of daily living. Only 15 items are used to calculate the GFI. GFI score range from 1 (no fatigue) to 50 (severe fatigue). (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.91 |
| Pregabalin 300 mg | -2.78 |
| Pregabalin 450 mg | -3.32 |
| Pregabalin 600 mg | -2.19 |
Pain visual analog scale (VAS): Participants assessed the severity of their pain using a 100 mm visual analog scale (VAS). The scale ranged from 0 (no pain) to 100 (worst possible pain), measurement on a scale corresponds to the magnitude of their pain. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | mm (Least Squares Mean) |
|---|---|
| Placebo | -10.30 |
| Pregabalin 300 mg | -12.86 |
| Pregabalin 450 mg | -17.75 |
| Pregabalin 600 mg | -11.74 |
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more disturbance. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 30.8 |
| Pregabalin 300 mg | 33.5 |
| Pregabalin 450 mg | 44.0 |
| Pregabalin 600 mg | 32.4 |
Acetaminophen (up to 4 gram/day as needed for pain relief) was an allowable concomitant medication as a rescue therapy. The total daily acetaminophen dose taken during double-blind treatment was calculated for each participant as: (total acetaminophen dose during the study) divided by (total number of study days). (NCT00333866)
Timeframe: Week 14
| Intervention | mg/day (Least Squares Mean) |
|---|---|
| Placebo | 460.65 |
| Pregabalin 300 mg | 449.14 |
| Pregabalin 450 mg | 508.53 |
| Pregabalin 600 mg | 724.42 |
FIQ: 20-item self-administered questionnaire designed to assess areas such as health status, progress, and outcomes in participants with fibromyalgia. 11 items related to physical functioning, other items assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. FIQ contains 10 sub-scales scored from 0 to 10, with higher scores indicating more impairment in the subscale attribute. Total score range from 0 to 100 with higher scores indicating more impairment. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| FIQ Physical Impairment (n=183,184,179,186) | FIQ Feel Good (n=182,184,178,183) | FIQ Work Missed (n=182,181,178,184) | FIQ Do Work (n=182,183,179,185) | FIQ Pain (n=183,184,179,185) | FIQ Fatigue (n=183,184,179,184) | FIQ Rested (n=183,184,179,185) | FIQ Stiffness (n=183,184,179,185) | FIQ Anxiety (n=183,184,179,185) | FIQ Depression (n=181,184,179,184) | |
| Placebo | -0.09 | -1.15 | -0.13 | -0.90 | -0.97 | -0.81 | -0.94 | -1.06 | -0.48 | -0.22 |
| Pregabalin 300 mg | -0.26 | -1.11 | -0.29 | -1.04 | -1.18 | -0.86 | -1.17 | -1.02 | -0.66 | -0.56 |
| Pregabalin 450 mg | -0.35 | -1.77 | -0.75 | -1.60 | -1.72 | -1.36 | -1.47 | -1.28 | -1.12 | -1.19 |
| Pregabalin 600 mg | -0.26 | -1.26 | -0.27 | -0.98 | -1.10 | -1.05 | -1.40 | -0.94 | -0.68 | -0.43 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |
|---|---|---|
| HADS Anxiety (HADS-A) Total | HADS Depression (HADS-D) Total | |
| Placebo | -0.31 | -0.11 |
| Pregabalin 300 mg | -0.42 | -0.33 |
| Pregabalin 450 mg | -0.81 | -0.70 |
| Pregabalin 600 mg | -0.90 | 0.04 |
Participant-rated 12 item questionnaire assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no), as well as a 9-item overall sleep problems index. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score minus lowest possible score divided by possible raw score range*100);total score range:0-100,higher score=more intensity of attribute. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Sleep Disturbance (n=183,183,177,185) | Snoring (n=172,174,174,177) | Shortness of Breath, Headache (n=182,182,177,184) | Quantity of Sleep (n=182,182,175,182) | Sleep Adequacy (n=183,183,179,185) | Somnolence (n=182,182,177,184) | Overall Sleep Problem Index (n=181,181,174,184) | |
| Placebo | -5.99 | -0.03 | -0.67 | 0.41 | 7.62 | -0.10 | -4.83 |
| Pregabalin 300 mg | -13.18 | 1.17 | -9.62 | 0.61 | 10.19 | 0.67 | -9.19 |
| Pregabalin 450 mg | -19.26 | 4.89 | -12.59 | 0.91 | 16.76 | 0.61 | -13.07 |
| Pregabalin 600 mg | -18.70 | 5.87 | -9.91 | 0.76 | 11.97 | 1.92 | -11.72 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0- 100, where higher score represents higher level of functioning. (NCT00333866)
Timeframe: Baseline, Week 14
| Intervention | Units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Functioning (n=184,184,177,186) | Physical Role Limitations (n=183,183,177,185) | Emotional Role Limitations (n=183,183,177,185) | Social Functioning (n=183,184,178,186) | Mental Health (n=183,184,178,186) | Bodily Pain (n=183,184,178,186) | Vitality (n=183,184,178,186) | General Health Perception (n=183,184,177,186) | Mental Component Score (n=182,183,176,184) | Physical Component Score (n=182,183,176,184) | |
| Placebo | 4.64 | 4.01 | -2.31 | 0.75 | -1.67 | 4.95 | 4.15 | 0.94 | -1.27 | 2.47 |
| Pregabalin 300 mg | 5.22 | 4.40 | 1.44 | 4.10 | 1.65 | 7.77 | 4.89 | 2.76 | 0.87 | 2.60 |
| Pregabalin 450 mg | 6.63 | 5.50 | 3.93 | 5.76 | 4.25 | 10.32 | 9.25 | 3.67 | 2.39 | 3.01 |
| Pregabalin 600 mg | 4.13 | 5.03 | 1.56 | 3.60 | 2.41 | 7.53 | 7.29 | 2.21 | 1.35 | 2.34 |
Daily quality of sleep diary consists of 11-point NRS ranging from 0(best possible sleep) to 10(worst possible sleep). Participants rated their quality of sleep during past 24 hours, self-assessment done daily upon awakening. Baseline=Last 7 available scores before taking study medication up to and including Day 1. The weekly mean quality of sleep score was based on LS Means using mixed model repeated measures ANCOVA, with treatment, center, week, and treatment-by-week interaction in the model and the baseline mean sleep score used as the covariate. Weekly mean sleep quality score is defined as the mean of the last 7 daily sleep diary entries. (NCT00333866)
Timeframe: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
| Intervention | Units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 (n=183,179,174,178) | Week 2 (n=180,172,168,174) | Week 3 (n=174, 164, 159,163) | Week 4 (n=165,157,155,156) | Week 5 (n=163, 150, 152,148) | Week 6 (n=159,145,148,144) | Week 7 (n=155,140,144,133) | Week 8 (n=149,133,142,127) | Week 9 (n=146,128,141,126) | Week 10 (n=144,125,139,126) | Week 11 (n=143,123,137,121) | Week 12 (n=141,121,135,119) | Week 13 (n=140,120,133,118) | Week 14 (n=134,115,128,111) | Overall (n=183,179,174,178) | |
| Placebo | -0.38 | -0.62 | -0.75 | -0.73 | -0.82 | -0.84 | -0.91 | -0.99 | -1.11 | -1.14 | -1.09 | -1.22 | -1.05 | -1.08 | -0.91 |
| Pregabalin 300 mg | -1.20 | -1.48 | -1.42 | -1.52 | -1.67 | -1.56 | -1.50 | -1.60 | -1.64 | -1.75 | -1.65 | -1.62 | -1.66 | -1.73 | -1.57 |
| Pregabalin 450 mg | -1.08 | -1.43 | -1.56 | -1.67 | -1.69 | -1.76 | -1.83 | -1.95 | -1.94 | -2.03 | -1.92 | -1.95 | -1.93 | -1.95 | -1.76 |
| Pregabalin 600 mg | -1.23 | -1.59 | -1.90 | -2.01 | -1.99 | -2.15 | -2.20 | -2.25 | -2.24 | -2.34 | -2.24 | -2.29 | -2.26 | -2.29 | -2.07 |
Number of participants with categorical change in overall status. PGIC: a participant-rated instrument assessing change in participant's overall status from baseline, on a scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00333866)
Timeframe: Week 14
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
| Placebo | 7 | 43 | 45 | 43 | 11 | 17 | 3 |
| Pregabalin 300 mg | 13 | 45 | 50 | 28 | 9 | 14 | 5 |
| Pregabalin 450 mg | 16 | 50 | 55 | 27 | 7 | 8 | 2 |
| Pregabalin 600 mg | 20 | 46 | 41 | 25 | 10 | 10 | 3 |
66 reviews available for gamma-aminobutyric acid and Behavior Disorders
| Article | Year |
|---|---|
Neurochemical mechanisms for memory processing during sleep: basic findings in humans and neuropsychiatric implications.
Topics: Brain; Brain Chemistry; Dopamine; gamma-Aminobutyric Acid; Humans; Memory; Mental Disorders; Nerve N | 2020 |
Role of NMDA receptor-mediated abnormalities of GABAergic interneurons in psychiatric disorders.
Topics: gamma-Aminobutyric Acid; Humans; Interneurons; Mental Disorders; Pyramidal Cells; Receptors, N-Methy | 2020 |
Systematic review of biological markers of therapeutic repetitive transcranial magnetic stimulation in neurological and psychiatric disorders.
Topics: beta-Endorphin; Biomarkers; Brain-Derived Neurotrophic Factor; gamma-Aminobutyric Acid; Humans; Ment | 2021 |
Effect of transcranial direct current stimulation on in-vivo assessed neuro-metabolites through magnetic resonance spectroscopy: a systematic review.
Topics: Adult; Aged; Case-Control Studies; Cerebellar Cortex; Dorsolateral Prefrontal Cortex; Female; gamma- | 2021 |
Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Hippocampus; Humans; Mental Disorders; Neural | 2017 |
Plasticity of the epigenome during early-life stress.
Topics: Age Factors; Animals; Brain-Derived Neurotrophic Factor; Disease Models, Animal; DNA Methylation; Ep | 2018 |
Positron emission tomography imaging of the γ-aminobutyric acid system.
Topics: Animals; Benzodiazepines; Brain; Carbon Radioisotopes; Flumazenil; Fluorine Radioisotopes; gamma-Ami | 2019 |
Gene expression profiling as functional readout of rodent models for psychiatric disorders.
Topics: Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Gene Expression Profiling; Humans; | 2013 |
Recent advances in sleep research.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Amines; Antiparkinson Agents; Biomedical Research; | 2013 |
GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies.
Topics: Adolescent; Adolescent Development; Alcoholism; Brain; Ethanol; gamma-Aminobutyric Acid; Humans; Mag | 2014 |
Mesencephalic GABA neuronal development: no more on the other side of oblivion.
Topics: Animals; GABAergic Neurons; gamma-Aminobutyric Acid; Gene Expression Regulation, Developmental; Huma | 2014 |
Biomarkers of psychiatric diseases: current status and future prospects.
Topics: Acetyltransferases; Alzheimer Disease; Biomarkers; Bipolar Disorder; Brain; Brain-Derived Neurotroph | 2015 |
Role of GABA(B) receptors in learning and memory and neurological disorders.
Topics: Animals; Behavior, Animal; Brain; Conditioning, Classical; Fear; gamma-Aminobutyric Acid; Humans; Le | 2016 |
Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Mental Disorders; Proton Magnetic Resonance Spectroscopy | 2016 |
The importance of the excitatory amino acid transporter 3 (EAAT3).
Topics: Animals; Excitatory Amino Acid Transporter 3; gamma-Aminobutyric Acid; Gene Expression Regulation; H | 2016 |
The complex nature of chronic pelvic pain.
Topics: Adult; Amines; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, | 2007 |
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.
Topics: Animals; Brain; Fluoxetine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Mood Disorders; Pregn | 2009 |
Bidirectional signaling of ErbB and Eph receptors at synapses.
Topics: Animals; Ephrins; gamma-Aminobutyric Acid; Humans; Mental Disorders; Models, Biological; Neuroglia; | 2008 |
Psychiatric concerns in pediatric epilepsy.
Topics: Adolescent; Amines; Anxiety Disorders; Bipolar Disorder; Child; Child, Preschool; Cyclohexanecarboxy | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Topics: Adult; Analgesics; Clinical Trials, Phase III as Topic; Comorbidity; Dose-Response Relationship, Dru | 2010 |
Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.
Topics: Animals; Central Nervous System Diseases; Deep Brain Stimulation; gamma-Aminobutyric Acid; Glutamic | 2011 |
[GABA: a functional duality? Transition during neurodevelopment].
Topics: Barbiturates; Benzodiazepines; Cation Transport Proteins; Central Nervous System; Cognition; Epileps | 2011 |
A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009).
Topics: Animals; Antipsychotic Agents; Epigenesis, Genetic; gamma-Aminobutyric Acid; History, 20th Century; | 2011 |
Assortment of GABAergic plasticity in the cortical interneuron melting pot.
Topics: Action Potentials; Adult; Animals; Cannabinoid Receptor Modulators; Cerebral Cortex; Cholecystokinin | 2011 |
Amygdala regulation of fear and emotionality in fragile X syndrome.
Topics: Amygdala; Animals; Conditioning, Psychological; Disease Models, Animal; Emotions; Fear; Fragile X Sy | 2011 |
The interesting interplay between interneurons and adult hippocampal neurogenesis.
Topics: Aging; Animals; gamma-Aminobutyric Acid; Hippocampus; Humans; Interneurons; Mental Disorders; Nervou | 2011 |
Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
Topics: Anxiety Disorders; Brain; Brain Chemistry; Creatine; Depressive Disorder; Epilepsy; GABA Agents; gam | 2003 |
[THERAPEUTIC ROLE AND SIGNIFICANCE OF GABA].
Topics: Aminobutyrates; Antihypertensive Agents; Cardiovascular System; gamma-Aminobutyric Acid; Humans; Men | 1964 |
[Neuropsychiatric disorders and GABA].
Topics: Central Nervous System Diseases; gamma-Aminobutyric Acid; Humans; Mental Disorders; Signal Transduct | 2004 |
Autism and 15q11-q13 disorders: behavioral, genetic, and pathophysiological issues.
Topics: Animals; Autistic Disorder; Brain; Chromosome Aberrations; Chromosomes, Human, Pair 15; gamma-Aminob | 2004 |
Pharmacotherapy of alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amitriptyline; Antidepressive Agents, Tricyclic; Comorb | 2005 |
The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women.
Topics: Affect; Depression, Postpartum; Female; gamma-Aminobutyric Acid; Humans; Menstruation; Mental Disord | 2006 |
Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin.
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fructose; Gabapentin; gam | 2007 |
Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amines; Behavior; Cyclohexanecarboxylic Acids; Dementia, | 2008 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
Stereopsychopharmacology: past, present and future.
Topics: Amphetamine; Animals; Brain; Cannabinoids; Dopamine; Endorphins; gamma-Aminobutyric Acid; Humans; Me | 1984 |
Neuroendocrine control of thyrotropin secretion.
Topics: Adult; Aging; Animals; Calcium; Cholecystokinin; Circadian Rhythm; Cyclic AMP; Dopamine; Estrogens; | 1981 |
gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Anticonvulsants; Binding Sites; Biological Transport, Acti | 1981 |
Glucocorticoid effects on central nervous excitability and synaptic transmission.
Topics: Acetylcholine; Animals; Biomechanical Phenomena; Brain; Cats; Cell Membrane; Central Nervous System; | 1982 |
Mechanism of anticonvulsant action of valproate.
Topics: Animals; Aspartic Acid; Cats; Central Nervous System; Epilepsy; gamma-Aminobutyric Acid; Half-Life; | 1982 |
Glutamate, GABA, and CNS disease: a review.
Topics: Brain; Brain Diseases; Energy Metabolism; Epilepsy; Ethanol; gamma-Aminobutyric Acid; Glutamates; Gl | 1983 |
Biological markers in mental disorders: post-mortem studies.
Topics: Age Factors; Alzheimer Disease; Basal Ganglia; Brain Chemistry; Choline O-Acetyltransferase; Circadi | 1984 |
Pharmacology of GABA.
Topics: 4-Aminobutyrate Transaminase; Anxiety Disorders; Autonomic Nervous System; Barbiturates; Benzodiazep | 1982 |
Postmortem studies in psychiatry.
Topics: Alcoholism; Alzheimer Disease; Brain Chemistry; Cholecystokinin; Depressive Disorder; Dopamine; Endo | 1984 |
Alterations of central GABAergic activity in neurologic and psychiatric disorders: evaluation through measurements of GABA and GAD activity in cerebrospinal fluid.
Topics: Aging; Carboxy-Lyases; Cold Temperature; Drug Stability; Female; gamma-Aminobutyric Acid; Glutamate | 1981 |
Basic aspects of GABA-transaminase in neuropsychiatric disorders.
Topics: 4-Aminobutyrate Transaminase; Aging; Animals; Blood Platelets; Brain; Brain Diseases; Female; gamma- | 1995 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
Morphine and its psychiatric implications.
Topics: Animals; Anxiety, Separation; Cathexis; Dopamine; gamma-Aminobutyric Acid; Gene Expression Regulatio | 1994 |
Contributions of the pedunculopontine region to normal and altered REM sleep.
Topics: Acetylcholine; Arousal; Basal Ganglia; Brain Stem; Evoked Potentials, Auditory; gamma-Aminobutyric A | 1997 |
Forced normalization: clinical and therapeutic relevance.
Topics: Animals; Cats; Cerebral Cortex; Comorbidity; Diagnosis, Differential; Dopamine; Electroencephalograp | 1999 |
Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology.
Topics: Animals; Animals, Newborn; Dopamine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Nervous Syst | 2000 |
The pathophysiology of agitation.
Topics: Aggression; Behavioral Symptoms; Bipolar Disorder; Dementia; Dopamine; gamma-Aminobutyric Acid; Huma | 2000 |
Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability.
Topics: Adolescent; Adult; Age of Onset; Animals; Antigens, CD; Bipolar Disorder; Brain; Cell Adhesion Molec | 2001 |
[Psycho-neuro-immuno-endocrinological psychiatry].
Topics: Adrenocorticotropic Hormone; Cytokines; gamma-Aminobutyric Acid; Humans; Hypothalamo-Hypophyseal Sys | 2001 |
Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.
Topics: Animals; Anticonvulsants; Baclofen; Brain; Diazepam; Dopamine Agonists; Dyskinesias; Emotions; GABA | 2001 |
Pharmacokinetics of new anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Felbamate; Fructo | 1998 |
Background and rationale for use of anticonvulsants in psychiatry.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cycloh | 1998 |
[Prolactin].
Topics: Adenoma; Adult; Amenorrhea; Breast Neoplasms; Dopamine; Estrogens; Female; gamma-Aminobutyric Acid; | 1978 |
Neurotransmitter interactions related to central dopamine neurons.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Central Nervous System; Dopam | 1978 |
Neurobiology and pharmacology of Huntington's disease.
Topics: Brain; Carnosine; Choline O-Acetyltransferase; Cholinergic Fibers; gamma-Aminobutyric Acid; Glutamat | 1977 |
[The significance of endorphins and gamma-aminobutyric acid in clinical psychopharmacology (author's transl)].
Topics: Anxiety; Bipolar Disorder; Deficiency Diseases; Depression; Endorphins; gamma-Aminobutyric Acid; Hum | 1978 |
Building a bridge between neurobiology and mental illness.
Topics: Bipolar Disorder; Brain; Brain Mapping; gamma-Aminobutyric Acid; Humans; Mental Disorders; Receptors | 1992 |
Interictal psychiatric disorders. Neurochemical aspects.
Topics: Anticonvulsants; Biogenic Amines; Depression; Epilepsy; Folic Acid; gamma-Aminobutyric Acid; Humans; | 1991 |
[Chemical and pharmacologic aspects of benzodiazepines].
Topics: Anti-Anxiety Agents; Benzodiazepines; Chemical Phenomena; Chemistry; gamma-Aminobutyric Acid; Half-L | 1989 |
[Use of fenibut in psychiatry and neurology and its place among other psychotropic drugs (review of the literature)].
Topics: Adult; Child; Drug Evaluation; gamma-Aminobutyric Acid; Humans; Mental Disorders; Nervous System Dis | 1989 |
[Implications of GABAergic synapses in neuropsychiatry].
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; | 1985 |
9 trials available for gamma-aminobutyric acid and Behavior Disorders
| Article | Year |
|---|---|
Cognitive behavioral therapy-related increases in cortical inhibition in problematic perfectionists.
Topics: Adolescent; Adult; Cerebral Cortex; Cognitive Behavioral Therapy; Female; gamma-Aminobutyric Acid; H | 2012 |
[Preventive and cessation therapy of mental disorders in patients with the acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Midd | 2012 |
Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation.
Topics: Acetates; Aged; Amines; Anti-Anxiety Agents; Comorbidity; Cyclohexanecarboxylic Acids; Dementia; Fem | 2003 |
Gabapentin reduces cocaine use among addicts from a community clinic sample.
Topics: Acetates; Adult; Amines; Cocaine-Related Disorders; Cyclohexanecarboxylic Acids; Diagnosis, Dual (Ps | 2004 |
Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions.
Topics: Adult; Age Distribution; Aged; Amines; Analgesics; Cohort Studies; Cross-Sectional Studies; Cyclohex | 2007 |
Retrospective study of vigabatrin and psychiatric behavioural disturbances.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; gamma-Aminobut | 1995 |
Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders.
Topics: Acetates; Adult; Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Behavioral S | 1998 |
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
Effect of sodium valproate on tardive dyskinesia.
Topics: Age Factors; Aged; Basal Ganglia Diseases; Blood Coagulation; Central Nervous System; Clinical Trial | 1976 |
60 other studies available for gamma-aminobutyric acid and Behavior Disorders
| Article | Year |
|---|---|
Single-nucleus transcriptome analysis reveals cell-type-specific molecular signatures across reward circuitry in the human brain.
Topics: Brain; Brain Mapping; Cell Nucleus; gamma-Aminobutyric Acid; Gene Expression Profiling; Genome-Wide | 2021 |
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders.
Topics: Adolescent; Communication; DiGeorge Syndrome; Evoked Potentials, Auditory; gamma-Aminobutyric Acid; | 2022 |
Gut microbes exacerbate systemic inflammation and behavior disorders in neurologic disease CADASIL.
Topics: Animals; CADASIL; Cytokines; gamma-Aminobutyric Acid; Gastrointestinal Microbiome; Mental Disorders; | 2023 |
Interplay between a Mental Disorder Risk Gene and Developmental Polarity Switch of GABA Action Leads to Excitation-Inhibition Imbalance.
Topics: Animals; Cell Polarity; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Gene Knockdown Technique | 2019 |
GABA and Negative Affect-Catatonia as Model of RDoC-Based Investigation in Psychiatry.
Topics: Affect; Catatonia; gamma-Aminobutyric Acid; Humans; Mental Disorders; Psychiatry | 2019 |
Behavior Disorders Caused by Perinatal Hypoxia in Juvenile Rats and Their Correction with GABA Derivative.
Topics: Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Female; Forelimb; gamma-Aminobu | 2017 |
Special Issue on Disease: New Advances in Psychiatry.
Topics: Animals; Brain; Cerebellum; Depression, Postpartum; Depressive Disorder; Female; gamma-Aminobutyric | 2019 |
Treatment of pediatric restless legs syndrome.
Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho | 2014 |
Neuropharmacological and neurobiological relevance of in vivo ¹H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Discovery; Excitatory Amino Acid Agents; GABA | 2014 |
Neuropsychiatric symptoms accompanying thrombocytopenia following pregabalin treatment for neuralgia: a case report.
Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Mental Disorders; Neuralgia; Pregabalin; | 2014 |
Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders.
Topics: Analysis of Variance; Case-Control Studies; Databases, Factual; Female; gamma-Aminobutyric Acid; Gen | 2016 |
Abuse of Gabapentin is Associated with Opioid Addiction.
Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar | 2016 |
Reduced gamma-aminobutyric acid is associated with emotional and behavioral problems in Prader-Willi syndrome.
Topics: Adolescent; Adult; Affective Symptoms; Brain; Case-Control Studies; Emotions; Female; gamma-Aminobut | 2016 |
Uncertainty assessment of gamma-aminobutyric acid concentration of different brain regions in individual and group using residual bootstrap analysis.
Topics: Adult; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Magnetic Resonance Spectroscopy; Male | 2017 |
The transcription factor Npas4 contributes to adolescent development of prefrontal inhibitory circuits, and to cognitive and emotional functions: Implications for neuropsychiatric disorders.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cognition; Emotions; Female; GABA Agents; gam | 2017 |
The Youth Mental Health Risk and Resilience Study (YouR-Study).
Topics: Adolescent; Adult; Biomarkers; Brain; Clinical Protocols; Early Diagnosis; Female; gamma-Aminobutyri | 2017 |
Usher syndrome and psychiatric symptoms: a challenge in psychiatric management.
Topics: Adult; Anorexia Nervosa; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosi | 2009 |
71-year-old man with chronic kidney failure and sudden change of mental status.
Topics: Academic Medical Centers; Aged; Amines; Analgesics; Confusion; Cyclohexanecarboxylic Acids; Dose-Res | 2009 |
Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders.
Topics: Adult; Amino Acid Transport System A; Calbindins; Databases, Genetic; Female; gamma-Aminobutyric Aci | 2011 |
Editorial: Etiological hypotheses of mental disorders at the molecular level.
Topics: Bipolar Disorder; Circadian Rhythm; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mental Disorders | 2010 |
Gabapentin and suicide attempts.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Databases, Factual; Female; Gabapentin; | 2010 |
The relationship between problem behavior and neurotransmitter deficiency in adolescents.
Topics: Adolescent; Adolescent Behavior; Dopamine; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Dis | 2010 |
[Therapy with gamma-aminobutyric acid (Gammalon) of mental and consciousness changes in neurosurgery].
Topics: Amino Acids; Butyrates; Consciousness; gamma-Aminobutyric Acid; Humans; Mental Disorders; Neurosurge | 1962 |
[gamma-Aminobutyric acid-pyridoxine in the treatment of states of irritability and connected nervous disorders].
Topics: Amino Acids; gamma-Aminobutyric Acid; Irritable Mood; Mental Disorders; Nervous System Diseases; Neu | 1962 |
[Effects of gamma-aminobutyric acid-pyridoxine in presenile and senile psychiatric disorders].
Topics: Amino Acids; Dementia; gamma-Aminobutyric Acid; Humans; Mental Disorders; Psychotic Disorders; Pyrid | 1962 |
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor | 1963 |
[Some experiences with the use of gamma-aminobutyric acid (GABA), especially in cases of coma and disorders caused by disturbances of cerebral circulation].
Topics: Amino Acids; Cerebrovascular Circulation; Cerebrovascular Disorders; Coma; Electroconvulsive Therapy | 1961 |
Behavioral correlates of GABAergic disruption in Alzheimer's disease.
Topics: Affect; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Cognition Disorders; Depressive Diso | 2007 |
Pregabalin induced neutropenia.
Topics: Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Mental Disorders; Middle Aged; Neutropenia | 2008 |
The roles of testicular orphan nuclear receptor 4 (TR4) in cerebellar development.
Topics: Animals; Behavior, Animal; Cerebellar Cortex; Cloning, Molecular; Death; gamma-Aminobutyric Acid; Me | 2008 |
[Pantogam in daily psychiatric practice].
Topics: Dose-Response Relationship, Drug; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Humans; Male; | 2007 |
gamma-Aminobutyric acid in CSF.
Topics: Evaluation Studies as Topic; Fluorometry; gamma-Aminobutyric Acid; Humans; Mental Disorders; Nervous | 1980 |
Anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Benzodiazepines; Convuls | 1982 |
[Old and new thought concepts on the biochemical principles of psychopharmcotherapy].
Topics: Acetylcholine; Brain; Depressive Disorder; Dopamine; gamma-Aminobutyric Acid; Humans; Mental Disorde | 1982 |
[Clinical pharmacology of the benzodiazepines].
Topics: Anti-Anxiety Agents; Benzodiazepines; Central Nervous System; Drug Interactions; gamma-Aminobutyric | 1982 |
Psychobiology of opioids.
Topics: Acetylcholine; Animals; Behavior; Brain; Brain Chemistry; Catecholamines; Circadian Rhythm; Consumma | 1984 |
Development of central neurotransmitter-specified neuronal systems: implications for pediatric neuro-psychiatric disorders.
Topics: Afferent Pathways; Animals; Brain Damage, Chronic; Cats; Central Nervous System; Cerebral Cortex; Ch | 1984 |
[Huntington chorea: report of 16 cases].
Topics: Adult; Aged; Brain Diseases; Chlorpromazine; Dementia; Diagnosis, Differential; Female; gamma-Aminob | 1983 |
Plasma GABA levels in psychiatric illness.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; gamma-Aminobutyric Acid; Humans; L | 1984 |
GABA and neuropsychiatric disorders.
Topics: Animals; Basal Ganglia; Central Nervous System Diseases; Epilepsies, Myoclonic; Epilepsies, Partial; | 1980 |
Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases.
Topics: Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Nervous System Diseases; Par | 1982 |
Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs.
Topics: Adult; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Middle Aged; Psy | 1980 |
Involvement of endogenous benzodiazepine receptor ligands in brain disorders: therapeutic potential for benzodiazepine antagonists?
Topics: Animals; Benzodiazepines; Brain Diseases; Central Nervous System Diseases; gamma-Aminobutyric Acid; | 1995 |
Gabapentin for behavioral dyscontrol.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Cycloh | 1995 |
[Medico-biological aspects of biochemistry of amines and other nitrogen bases].
Topics: Amine Oxidase (Copper-Containing); Animals; Antidepressive Agents; Antioxidants; Brain; Carbazoles; | 1995 |
The placebo: from specificity to the non-specific and back.
Topics: Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Neurotransmitter Agents; Placebo Ef | 1993 |
Vigabatrin and behaviour disorders: a retrospective survey.
Topics: Anticonvulsants; Electroencephalography; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disor | 1996 |
Pivagabine (Tonerg). A novel psychoactive drugs.
Topics: gamma-Aminobutyric Acid; Humans; Mental Disorders; Psychotropic Drugs | 1997 |
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim | 1999 |
Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease.
Topics: Acetates; Aged; Aged, 80 and over; Alzheimer Disease; Amines; Anticonvulsants; Cholinesterase Inhibi | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
Gabapentin for behavioral dyscontrol with mental retardation.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Drug Th | 2001 |
Gabapentin in complicated school refusal.
Topics: Acetates; Adolescent; Amines; Comorbidity; Cyclohexanecarboxylic Acids; Cyclohexanols; Drug Therapy, | 2002 |
Neurochemical basis of the therapeutic effect of gamma-aminobutyric acid and its derivatives.
Topics: 4-Aminobutyrate Transaminase; Animals; Axonal Transport; Brain; Brain Diseases; Epilepsy; gamma-Amin | 1978 |
Predictive tests in Huntington's disease.
Topics: Age Factors; Electroencephalography; Eye Movements; Female; gamma-Aminobutyric Acid; Genetic Counsel | 1976 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
Cerebrospinal fluid values for monoamine metabolites, gamma-aminobutyric acid, and other amino compounds in Rett syndrome.
Topics: Adolescent; Biogenic Amines; Brain Diseases; Child; Child Behavior Disorders; Child, Preschool; Deve | 1988 |
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
Topics: Aged; Aminocaproates; Carnosine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Mental D | 1987 |
[Round table. GABA and neuro-psychiatric pathology. Fez (Morocco), 24-25 October 1986. Proceedings].
Topics: Animals; Brain Diseases; gamma-Aminobutyric Acid; Humans; Mental Disorders | 1987 |
A model of the vertebrate nervous system based largely on disinhibition: a key role of the GABA system.
Topics: Adaptation, Psychological; Aminobutyrates; Animals; Brain Mapping; gamma-Aminobutyric Acid; Humans; | 1973 |